Cytokinetics Heart Drug Succeeds in Phase 3 Trial, Shares Fall
Cytokinetics achieved a major milestone, becoming the first company to succeed in a Phase 3 clinical trial for non-obstructive hypertrophic cardiomyopathy. The news was announced on Friday, causing…
Cytokinetics achieved a major milestone, becoming the first company to succeed in a Phase 3 clinical trial for non-obstructive hypertrophic cardiomyopathy. The news was announced on Friday, causing the company's stock to decline.
Original: https://www.investors.com/news/technology/cytokinetics-acacia-study-non-obstructive-hcm/
insigtX content is informational and educational, not investment advice.